87 results about "Severe hypothyroidism" patented technology

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

The invention belongs to the technical field of immunodiagnosis, and discloses a thyroxine (T4) enzymatic chemiluminescence quantitative determination kit. The kit disclosed by the invention consists of a T4 standard product, an antibody pre-coated reaction plate, a horseradish peroxidase marker, diluent, cleaning mixture, and chemiluminescence substrate liquid. The kit disclosed by the invention has the advantages of quickness, handiness, sensitiveness, cheapness and high repeatability, and is an important index for diagnosis and therapeutic evaluation of hyperthyroidism and hypothyroidism. The invention has high clinic use value. The invention also provides a method to prepare the kit.

Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.

The invention relates to a Chinese medicine composite used for treating hypothyroidism. The Chinese medicine composite is made by radix codonopsitis, epimedium powder, cuscuta, pulp of dogwood fruit, cistanche deserticola, Chinese angelica, milk veteh, medlar, radix morindae officinalis, largehead atractylodes rhizome, cimicifuga foetida, glycyrrhiza, bupleurum, cassia twig, radix rehmanniae and / or a carrier acceptable for pharmacy. The invention also relates to a preparation method of the Chinese medicine composite. The Chinese medicine composite used for treating hypothyroidism has the functions of warming kidney to invigorate yang, replenishing Qi, dispelling cold, nourishing yin for moistening dryness and strengthening spleen. The Chinese medicine composite used for treating hypothyroidism can be applicable for protecting against cold, dry skin and olighidria, pale and waxen face and bloated face caused by the hypothyroidism.

A method for screening a patient for angioinhibition resistance and treating said patient having a disease susceptible to treatment via an anti-angiogenic agent. The screening method includes an assay for identifying the presence of angioinhibition resistance in patients by collecting patient blood or serum and subjecting it to a Chick Chorioallantoic Membrane (CAM) angiogenesis assay configured for accepting a human tumor wherein the human tumor xenograft includes a vasculature system. The screening method and assay further includes steps that include using the CAM results for identifying the endogenous pro-angiogenic non-peptide hormone concentrations of the blood sample by calculating the vascular activity of the vasculature system of the human tumor xenograft in the presence of anti-angiogenic drugs and inducing in the patient, a state of subclinical hypothyroidism prior to commencing anti-angiogenic treatment.

The invention provides a health-care food for adjuvant therapy of hypothyroidism and a preparation method thereof. The formula comprises 15-25% of dried ginger, 1-5% of ginseng, 5-15% of prepared common monkshood daughter root, 5-15% of Chinese angelica, 9-20% of Indian buead, 10-25% of common macrocarpium fruit, 5-15% of south dodder seed and 10-25% of barbary wolfberry fruit, the preparation method comprises the following steps: removing impurities, cleaning, drying, grinding, sieving and uniformly mixing; and the health-care food can be prepared into formulations comprising capsules, tea bags, tablets, pills, syrup and decoction pieces. The health-care food can be used for the adjuvant therapy of the hypothyroidism and also has multiple effects of restoring yang, promoting blood circulation, stagnating qi in skin, dredging joints in four limbs, opening internal organs, opening heart, benefiting intelligence, promoting blood circulation, breaking stubborn masses, removing pathogenic qi, generating muscles, treating inward invasion of pathogenic cold, edema and tumescence and the like; and furthermore, the health-care food can be used for effectively enhancing the immunity of a human body, and has a great therapeutic effect for diabetes and high sugar in bloody urine.

This invention discloses an indicator paper for thyrotropin diagnosis, which comprises one testing area, one normal high limit control area, one normal low limit control area and a gold immune complex dry area. This invention also discloses the application of the indicator paper for thyrotropin diagnosis. It is a regular testing method to judge hypothalamus- hypophysis-thyroid axis function. This invention can be also used in the following fields: screening primary thyroid dysfunction such as hypothyroidism and hyperthyroidism; thyroid hormone substitution and abatement therapeutic efficacy detecting; hyperthyroidism and hypothyroidism patient diagnosis; thyroid function monitoring of iodine-assisting crowd and thyroid dysfunction of non-thyroid continuous monitoring.

The invention relates to an application of a traditional Chinese drug composite, namely a sini decoction, in preparing a drug for treating hypothyroid sexual function reduction. When researching the effect of the sini decoction on rat models with hypothyroid sexual function reduction, the rats are found to experience obvious increase of testosterone level, obvious rise of T level in blood serum after being lavaged with the sini decoction; meanwhile, the level of thyroid hormone gradually recovers, thus indicating that the sini decoction can improve the generating function of rats with hypothyroid sexual function reduction and enhance sexual function by adjusting the secretion of sex hormone. The invention adds the new application of the sini decoction in treating hypothyrosis, especially hypothyroid sexual function reduction and extends indications for the traditional Chinese drug composite, namely the sini decoction.

The present invention relates to a pharmaceutical composition for preventing or treating thyroid diseases and a food composition for improving thyroid function, comprising an extract from Lonicera caerulea L. car. Edulis fruits as an active ingredient.The composition of the present invention may be useful for preventing or treating thyroid diseases such as hypothyroidism, hyperthyroidism, thyroid nodule, or thyroditis, and improving thyroid function. Since the extract from Lonicera caerulea L. car. Edulis fruits, which is an active ingredient of the present invention, is derived from natural products, there is no concern for side effects such as toxicity compared to synthetic medicine.

Provided are methods for the detection and diagnosis of Hypothyroidism. The methods are based on the discovery that altered levels of selected analytes in sample fluid, typically blood samples, of patients are supportive of a diagnosis of Hypothyroidism. At least twenty-four new biomarkers for hypothyroidism are thus disclosed (singly or in any combination), Thyroid Stimulating Hormone, Interleukin-12p40, Tumor Necrosis Factor Alpha, Tissue Factor, Interleukin-15, Insulin, Immunoglobulin E, Growth Stimulating Hormone, Calcitonin, Prostate-Specific Antigen, Interleukin-4, Granulocyte Macrophage Colony Stimulating Factor, Matrix Metalloproteinase 9, Lymphotactin, Fatty Acid Binding Protein, Alpha Fetoprotein, Alpha-2 Macroglobulin, Serum Glutamic Oxaloacetic Transaminase, Matrix Metalloproteinase 3, Cancer Antigen 125, Mumps Antibody, Double Stranded DNA Antibody, Proliferating Cell Nuclear Antigen Antibody, Smith Antibody, or Herpes Simplex Virus 1 Glycoprotein D Antibody. Altogether the concentrations of one or more of these analytes, as well as Thyroid Stimulating Hormone, or any combination thereof, provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from Hypothyroidism. Kits containing reagents to assist in the analysis of fluid samples are also described.

Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

The invention discloses a thyroid-stimulating hormone detection test paper, which comprises a plastic substrate, a sample pad and a water-absorbing pad are arranged on the plastic substrate, a protective film is arranged on the sample-loading pad and the water-absorbing pad, and the bottom between the sample-loading pad and the water-absorbing pad is A nitrocellulose membrane is provided, and the connection end of the sample pad is provided with solid-phase colloidal gold, and one end of the solid-phase colloidal gold is overlapped with one end of the nitrocellulose membrane, and the nitrocellulose membrane is sequentially coated with detection Line and quality control line; the manufacturing method steps include: preparation of nitrocellulose membrane; marking and solid phase of polyester fiber strip; assembly and cutting. The present invention applies the principle of double-antibody sandwich method and immunochromatography to qualitatively detect human thyroid-stimulating hormone (TSH) in urine. The detection steps are relatively simple, and the results can be observed within 10 minutes. General users can perform the detection by themselves. The present invention judges whether there is a risk of hypothyroidism by comparing the color depth of the detection line with the matched color card.

Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and / or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.

The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.

The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders is maintained, while thyroid-related and thyroid axis-related side effects are reduced or eliminated.

The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.

The invention relates to an injection medicament for treating hyperthyroid, which comprises the following components by weight part: 2 to 5 milligrams of dexamethasone injection, 0.5 to 1 milligram of octreotide injection, and 10 to 20 milligrams of ciclosporin A. Immune preparations such as the dexamethasone injection, the octreotide injection, the ciclosporin A and the like are adopted for treating the hyperthyroid by locally injecting the thyroid, the volume of the tumid thyroid is remarkably shrunk, and the function of the thyroid basically recovers within two months, so the injection medicament has remarkable curative effect, and can remarkably improve the remission rate of hyperthyroid and reduce the rate of relapse. Serious abnormal change, hypothyroidism and parathyroid hypofunction are not caused, and laryngeal recurrent nerve injury is also not caused. Through more than 580 cases of clinical therapy in related hospitals, the volume of the tumid thyroid is remarkably shrunk after therapy, clinical symptoms disappear, allergic response and complications are not caused, the effective percentage is nearly 100 percent, and the cure rate is as high as 98 percent.

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

The invention provides a TSH (thyroid stimulating hormone) quantitative detection kit based on time-resolved fluoroimmunoassay, applicable to clinical screening of neonatal hypothyroidism. The preparation method of the kit is characterized by comprising the following steps of: 1, separating an antibody conjugate (Eu-Anti-TSH) from free rare earth ions (Eu<3+>) by using a specific chromatograph column; (2) using a bifunctional chelator (DTTA) for marking, wherein one end of the bifunctional chelator is chelated with rare earth ions (Eu) and the other end of the bifunctional chelator is connected with -NH2 of protein; adding beta-NTA to reinforcing liquid and regulating the concentration so that the fluorescence intensity of a finally obtained reagent is improved; and (4) adding a substitute Proclin300 for sodium azide to an analysis buffer system. Based on the characteristics of the steps in the preparation method, the TSH quantitative detection kit based on time-resolved fluoroimmunoassay can be produced and other in vitro diagnosis detection reagents can be developed.

The invention relates to a hypothyroidism treatment traditional Chinese medicine composition, which is characterized in that bulk drugs comprise, by weight: 9 g of angelica, 15 g of white peony root, 15 g of Chinese thorowax root, 10 g of nutgrass galingale rhizome, 10 g of wenchow turmeric root tuber, 10 g of common burreed tuber, 10 g of blue turmeric rhizome, 30 g of salvia miltiorrhiza, 10 g of radix et rhizoma rhei from Sichuan of China, 30 g of ma-yuen jobstears seed, 12 g of glossy privet fruit, 12 g of eclipta prostrata, 15 g of herba epimedii, 15 g of dodder, 6 g of chicken's gizzard membrane, 30 g of pumice stone, 6 g of hirsute bugleweed herb, 30 g of suberect spatholobus stem, and 6 g of prepared liauorice root, wherein the 19 traditional Chinese medicines are placed in 1200 ml of water to soak for 30 min, decoction is performed for 35 min by using mild fire, filtration is performed, and residues are removed to prepare 500 ml of a traditional Chinese medicine liquid, wherein the traditional Chinese medicine liquid is the hypothyroidism treatment traditional Chinese medicine composition. The hypothyroidism treatment traditional Chinese medicine composition has the following characteristics that: the traditional Chinese medicine raw materials are reasonably matched, and effects of symptom and root cause treatment, and simultaneous application of purging-tonifying therapy are provided; problems of unacceptable tonifying due to deficiency, and no treatment effect are solved; and effects of excessive qi removing, blood circulation activating, no body resistance damage, consumptive disease tonification and no stagnation are provided, and a purpose of hypothyroidism treatment is achieved. In addition, the hypothyroidism treatment traditional Chinese medicine composition has advantages of convenient raw material obtaining, low cost, significant and lasting treatment effect, low toxic-side effect, and the like.

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

The invention relates to an improved method for predicting the onset of, diagnosing, prognosticating and / or treating dementing diseases. The method comprises determining the level of heme oxygenase-1 suppressor (HOS) activity and / or factor in tissue or body fluid obtained from a patient, and comparing said level with the corresponding level of HOS activity and / or factor in corresponding tissue or body fluid obtained from at least one control person. The tissue or body fluid is suitably blood, plasma, lymphocytes, cerebrospinal fluid, urine, saliva, epithelia or fibroblasts. The method is useful where the dementing disease is any of Alzheimer Disease, Age-Associated Cognitive Decline, Mild Cognitive Impairment, Parkinson disease with dementia, Progressive Supranuclear Palsy, Vascular (i.e. multi-infarct) Dementia, Lewy Body Dementia, Huntington's Disease, Down's syndrome, normal pressure hydrocephalus, corticobasal ganglionic degeneration, multisystem atrophy, head trauma, neurosyphilis, Creutzfeld-Jacob disease and other prion diseases, HIV and other encephalitides, and metabolic disorders such as hypothyroidism and vitamin B12 deficiency. The method may also prove useful in differentiating the“pseudodementia” of depression from Alzheimer disease.

The invention discloses application of citrus fruit volatile oil in preparing a food and a drug for regulating internal secretion to relieve primary dysmenorrhea and female climacteric syndrome and alleviating hypothyroidism and prostatitis. The application range of the citrus fruit volatile oil is widened and a new way of regulating internal secretion to relieve primary dysmenorrhea and female climacteric syndrome and alleviating endocrine diseases of hypothyroidism prostatitis and the like is provided.

Traditional Chinese medicine pills for treating hypothyroidism are mainly prepared by mixing and extruding the following traditional Chinese medicines in parts by weight: 9 parts of monkshood, 12 parts of cassia twig, 12 parts of prepared rehmannia roots, 8 parts of rhizoma alismatis, 10 parts of radix codonopsis, 10 parts of white peony roots, 9 parts of angelica sinensis, 10 parts of ligusticum wallichii, 10 parts of Chinese yam, 8 parts of poria cocos, 10 parts of antler gum, 5 parts of Chinese thorowax roots and 10 parts of chrysanthemum morofolium ramat. The Traditional Chinese medicine pills for treating hypothyroidism are demonstrated by the pathologies of spleen-kidney yang deficiency, qi-blood deficiency and deficiency of liver-yin and kidney-yin, and combine the traditional Chinese medicines with the efficacies of warming kidney, strengthening spleen, replenishing qi, nourishing blood, nourishing yin and tonifying qi to treat hypothyroidism dialectically; the medical theory is correct; the curative effect in practice is remarkable.

The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 to R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.

The invention discloses a traditional Chinese medicine preparation for treating subclinical hypothyroidism. The traditional Chinese medicine preparation comprises the following raw materials in parts by weight: 9-11 parts of root of three-nerved spicebush, 2-4 parts of amethyst, 1-3 parts of purple cassia bark, 6-10 parts of rehmannia glutinosa, 4-6 parts of boxthorn root, 2-4 parts of semen cuscutae, 5-7 parts of folium cortex eucommiae, 2-4 parts of semen raphani, 1-3 parts of cinnamon, 5-7 parts of seaweed meal, 3-5 parts of cuttlefish bone powder, 2-4 parts of morinda officinalis, 5-7 parts of raspberry, 3-5 parts of placenta hominis, 1-3 parts of peanut shell,1-3 parts of amaranthus viridis, 4-6 parts of centella aslatlca urban, 10-15 parts of lotus leaves, 2-4 parts of creeping oxalis, 1-3 parts of fewleaf schnabelia herb and 1-3 parts of large-leaved cayratia. The crude drugs selected by the traditional Chinese medicine preparation have the effects of soothing liver-qi stagnation, regulating vital energy and relieving pain, invigorating spleen and replenishing qi, warming and invigorating kidneys yang, filling essence and blood, dissolving phlegm and removing stasis, clearing lung and eliminating phlegm and relieving swelling and relieving pain. The traditional Chinese medicine preparation is good in curative effect, quick to take effect, high in recovery rate and free of toxic and side effects.